📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
131 announcements match the current filters (relevance ≥ 5).
Piramal Pharma Receives US FDA EIR for Lexington Facility; Inspection Successfully Closed
Piramal Pharma Limited has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Lexington, Kentucky, USA. The inspection, which was previously reported in December 2025, has been classified as Voluntary Action Indicated (VAI). This classification signifies the successful closure of the regulatory audit, ensuring the facility meets US compliance standards. The clearance is a positive development for the company's contract development and manufacturing operations in the US market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Lexington, USA manufacturing site.
The inspection status is classified as Voluntary Action Indicated (VAI), marking a successful closure.
The audit was originally initiated and disclosed on December 11, 2025.
Successful clearance ensures uninterrupted operations and compliance for products manufactured at this facility for the US market.
👀 What to Watch
This regulatory clearance removes a potential overhang on the stock and validates the company's quality systems. Investors should view this as a positive signal for the company's US-based manufacturing capabilities.
CRISIL Assigns 'A/Stable' Rating to Aditya Infotech's Rs 555 Cr Bank Facilities
Aditya Infotech Limited, known for the CPPLUS brand, has been assigned a 'CRISIL A/Stable' credit rating for its bank loan facilities totaling Rs 555 Crore. This rating assignment follows the revocation of a previous suspension by CRISIL, indicating a return to active monitoring and improved transparency. Concurrently, the company has withdrawn its previous rating of 'CARE BBB+; Stable' from CARE Ratings. The shift to an 'A' category rating from CRISIL represents a significant improvement in the company's perceived creditworthiness and financial stability.
Key Highlights
CRISIL assigned a Long Term Rating of 'CRISIL A/Stable' for bank loan facilities worth Rs 555 Crore.
The rating assignment follows the revocation of a previous suspension by CRISIL Ratings.
The company has officially withdrawn its previous 'CARE BBB+; Stable' rating from CARE Ratings.
The transition to an 'A' rating signifies a stronger credit profile compared to the previous 'BBB+' investment grade.
👀 What to Watch
Investors should view this credit rating upgrade as a positive signal of the company's strengthening balance sheet and reduced default risk. This improved rating may help the company negotiate better interest rates on future borrowings, potentially improving net margins.
Piramal Pharma Completes Acquisition of Kenalog® Branded Injectable from Bristol-Myers Squibb
Piramal Pharma's subsidiary, Piramal Critical Care B.V., has successfully completed the acquisition of the Kenalog® brand and associated products from Bristol-Myers Squibb. This strategic move is aimed at strengthening the company's Complex Hospital Generics portfolio, which is a high-margin segment. The acquisition enhances Piramal's market presence across the United States, Europe, and the Asia Pacific region. This completion follows the initial agreement announced in January 2026, marking a significant milestone in the company's inorganic growth strategy.
Key Highlights
Successful completion of Kenalog® brand acquisition from Bristol-Myers Squibb (BMS).
Acquisition executed via Piramal Critical Care B.V., a step-down wholly owned subsidiary.
Strengthens the 'Complex Hospital Generics' portfolio across global markets.
Expands operational footprint in key geographies including the US, Europe, and Asia Pacific.
Follows through on the initial disclosure made on January 28, 2026.
👀 What to Watch
Investors should look for improved margins in the Critical Care segment as branded products typically offer better pricing power. Monitor upcoming quarterly earnings for the first full-quarter contribution of Kenalog® to the top line.
Aditya Infotech Shareholders Approve ESOP 2024 and Director Remuneration Revisions
Aditya Infotech Limited (CPPLUS) has successfully passed six special resolutions via postal ballot with a total voter turnout of 90.14%. Key approvals include the ratification of the Employee Stock Option Plan (ESOP) 2024 and its extension to employees of subsidiary and group companies. Shareholders also approved remuneration revisions for the Chairman, Managing Director, and Whole-Time Director. Notably, while resolutions passed with over 93% overall support, public non-institutional investors showed significant dissent, voting over 98% against the ESOP and MD remuneration proposals.
Key Highlights
Ratification of Aditya Infotech ESOP Plan 2024 approved with 93.33% majority.
Remuneration revision for Chairman Hari Shanker Khemka received the highest support at 99.56%.
Extension of ESOP benefits to group and subsidiary employees passed with 93.33% of votes in favour.
Significant retail dissent noted with public non-institutional investors voting 98.36% against the ESOP ratification.
Total votes polled represented 10,61,85,572 shares out of 11,77,98,084 total outstanding shares.
👀 What to Watch
Investors should monitor the potential equity dilution from the new ESOP plan and ensure that the revised management remuneration remains aligned with the company's long-term profit growth. The high level of retail investor dissent on specific resolutions warrants a closer look at the company's governance communication.
Rajshree Polypack Clarifies Identical Standalone & Consolidated Q2 FY26 Results
Rajshree Polypack Limited (RPPL) responded to NSE's clarification request regarding identical standalone and consolidated financial figures for the quarter ended September 30, 2025. The company explained that its sole joint venture, Olive Ecopak Private Limited, has accumulated losses exceeding RPPL's investment, resulting in a carrying value of zero under Ind AS 28. Consequently, no further losses are recognized in the consolidated statement, making it identical to the standalone results. For Q2 FY26, the company reported a total income of ₹8,837.07 Lakhs and a net profit of ₹459.51 Lakhs.
Key Highlights
Q2 FY26 Revenue from Operations stood at ₹8,642.85 Lakhs, up from ₹8,251.65 Lakhs in the previous quarter.
Net Profit for the quarter was ₹459.51 Lakhs with a Basic EPS of ₹0.62.
Identical standalone and consolidated figures occur because the JV investment value is nil due to accumulated losses.
A revision in the useful life of machinery from 15 to 20-25 years reduced depreciation by ₹147.06 Lakhs for the half-year.
The company converted 1,50,000 share warrants into 9,00,000 equity shares following a stock split.
👀 What to Watch
Investors should recognize that the identical reporting is a technical accounting outcome of JV losses and not a reporting error. Monitor the impact of revised depreciation on long-term margins and the eventual turnaround of the Olive Ecopak joint venture.
Aditya Infotech Seeks Approval for ESOP 2024 Ratification and Director Remuneration Revisions
Aditya Infotech Limited (CPPLUS) has issued a postal ballot notice seeking shareholder approval for the ratification of its Employee Stock Option Plan 2024. The company also proposes extending ESOP benefits to employees of subsidiary, associate, and holding companies to align group-wide interests. Furthermore, the ballot includes special resolutions to revise the remuneration packages for three key directors: Hari Shanker Khemka, Aditya Khemka, and Ananmay Khemka. The e-voting period for these resolutions is scheduled from February 27 to March 28, 2026.
Key Highlights
Ratification of Aditya Infotech Employee Stock Option Plan 2024 involving equity shares of Re. 1 face value.
Extension of ESOP benefits to eligible employees across Group, Subsidiary, Associate, and Holding companies.
Proposed revision in remuneration for the Chairman, Managing Director, and Whole-Time Director via special resolutions.
Amendment to the Articles of Association (AoA) of the company is also under consideration.
E-voting period set for 30 days, starting February 27, 2026, with results expected by March 31, 2026.
👀 What to Watch
Investors should examine the explanatory statement for the specific quantum of remuneration increases and the potential equity dilution from the ESOP plan. Ensure that the proposed management compensation is commensurate with the company's financial performance and growth trajectory.
CPPLUS Promoters Sell 2% Stake to Comply with Minimum Public Shareholding Norms
Promoters of Aditya Infotech Limited (CPPLUS) have successfully offloaded a 2.00% stake in the company through the open market. This transaction, involving 23,55,961 equity shares, was conducted to meet the mandatory Minimum Public Shareholding (MPS) requirements set by SEBI. The sellers included the Hari Khemka Business Family Trust and Mr. Rishi Khemka. This move ensures the company remains compliant with listing regulations and increases the public float of the stock.
Key Highlights
Total of 23,55,961 equity shares sold, representing 2.00% of the total paid-up equity capital.
Hari Khemka Business Family Trust sold 17,66,971 shares (1.50% stake).
Mr. Rishi Khemka sold 5,88,990 shares (0.50% stake).
The sale was executed via the open market route specifically for MPS compliance under SEBI regulations.
The transaction was completed within the stipulated timeline as per the company's previous intimation.
👀 What to Watch
This is a routine regulatory compliance event and should not be viewed as a negative signal regarding the company's fundamentals. Investors can expect slightly improved liquidity in the counter due to the increased public float.
Aditya Infotech Promoters to Sell Up to 2% Stake for MPS Compliance
Promoters of Aditya Infotech (CPPLUS), including Hari Khemka Business Family Trust and Mr. Rishi Khemka, have announced their intention to sell up to 2% of the company's equity. The sale involves 23,55,961 shares and is scheduled to take place between February 25, 2026, and March 05, 2026. This divestment is specifically aimed at meeting SEBI's Minimum Public Shareholding (MPS) requirement, as the current promoter holding stands at 76.74%. The transaction will be conducted through the open market to increase the public float to the mandatory 25%.
Key Highlights
Promoters to divest up to 2% stake, equivalent to 23,55,961 equity shares.
Current promoter and promoter group shareholding is 76.74%, exceeding the 75% limit.
Divestment window is set from February 25, 2026, to March 05, 2026.
Purpose of the sale is to comply with SEBI Minimum Public Shareholding (MPS) norms.
Promoter group has undertaken not to purchase any shares on the days of the sale.
👀 What to Watch
Investors should anticipate potential short-term price volatility due to the increased supply of shares in the open market. However, this is a routine regulatory requirement that will improve the stock's liquidity over the long term.
RPPL Clarifies Identical Q3 Standalone & Consolidated Results; Reports ₹215.56 Lakhs Net Profit
Rajshree Polypack Limited (RPPL) clarified to the NSE that its standalone and consolidated figures for Q3 FY26 are identical because its joint venture, Olive Ecopak, has accumulated losses exceeding RPPL's investment value. Under Ind AS 28, the company stopped recognizing further JV losses once the carrying amount reached zero. For the quarter ended December 31, 2025, RPPL reported a net profit of ₹215.56 lakhs, recovering from a loss of ₹4.81 lakhs in the same period last year. Revenue from operations remained relatively flat at ₹7,162 lakhs.
Key Highlights
Reported Q3 net profit of ₹215.56 lakhs vs a net loss of ₹4.81 lakhs in Q3 FY25.
Joint Venture (Olive Ecopak) incurred a loss of ₹213.72 lakhs for the quarter, which was not recognized in consolidated results due to nil investment value.
Revenue from operations for the quarter stood at ₹7,162 lakhs compared to ₹7,270 lakhs YoY.
Converted a ₹4,050 lakh loan previously given to the Joint Venture into equity/unsecured instruments.
Revision of machinery useful life from 15 to 25 years reduced nine-month depreciation by ₹249.05 lakhs, boosting reported profits.
👀 What to Watch
Investors should monitor the performance of the Joint Venture, Olive Ecopak, as RPPL has significant exposure through the ₹4,050 lakh loan conversion. While the return to profitability is positive, note that a portion of the profit improvement stems from a change in depreciation accounting.
Prakash Pipes Acquires 26% Stake in BECIS Solar 3 for Captive Power Project
Prakash Pipes Limited has completed the acquisition of a 26% equity stake in BECIS Solar 3 Private Limited for a total investment of ₹3,58,379. The company was allotted 3,51,352 equity shares at a price of ₹1.02 per share, including a small premium. This strategic investment is intended to develop a solar power project to supply captive power to the company's operations. The move complies with the Electricity Rules, 2005, and aims to reduce long-term energy costs.
Key Highlights
Acquired 26% equity share capital of BECIS Solar 3 Private Limited
Total investment of ₹3,58,379 for 3,51,352 fully paid-up equity shares
Shares issued at face value of ₹1 each with a premium of ₹0.02 per share
Investment aimed at developing a solar power project for captive power supply
Move aligns with Electricity Rules, 2005 for operational cost optimization
👀 What to Watch
While the financial outlay is small, this is a positive step toward energy self-sufficiency and ESG compliance. Investors should view this as a long-term cost-saving measure for the company's manufacturing operations.
CP PLUS (Aditya Infotech) Secures Title Sponsorship for Punjab Kings in IPL 2026
Aditya Infotech Limited (CPPLUS) has announced its role as the Title Sponsor for the Punjab Kings IPL franchise for the 2026 season. This high-profile partnership is designed to boost brand visibility and consumer engagement across India through digital campaigns and stadium activations. The company aims to leverage the IPL's massive reach to reinforce its leadership in the security and surveillance sector. While the financial outlay for the sponsorship was not disclosed, it marks a significant step in the company's brand-building strategy.
Key Highlights
CP PLUS named Title Sponsor for Punjab Kings for the upcoming IPL 2026 season.
Partnership includes digital-first storytelling and immersive fan-focused experiences.
Strategic move to engage a nationwide audience and promote 'Make in India' security solutions.
CP PLUS operates the largest integrated manufacturing facility for security products in Kadapa, Andhra Pradesh.
👀 What to Watch
Monitor the company's marketing expenditure and its impact on operating margins in the 2026 fiscal year. Assess if the increased brand visibility translates into higher market share in the retail security segment.
Prakash Pipes Receives ₹75 Crore Loan Repayment from Promoter Entity Prakash Industries
Prakash Pipes Limited (PPL) has announced the successful recovery of a ₹75 crore loan from its promoter group entity, Prakash Industries Limited. The loan was originally extended as a related-party transaction on an arm's length basis and had received all necessary regulatory and board approvals. This repayment significantly enhances PPL's cash position and reduces the risk associated with related-party receivables. Such a move is generally viewed as a positive signal for corporate governance and balance sheet strength.
Key Highlights
Full repayment of ₹75 crore loan by promoter group entity Prakash Industries Limited
Transaction conducted on an arm's length basis and in the ordinary course of business
Repayment improves the company's liquidity and reduces related-party financial exposure
Compliance with SEBI (LODR) Regulation 23 and 30 confirmed by the company
👀 What to Watch
Investors should view this as a positive development that de-risks the balance sheet. Monitor how the company utilizes this ₹75 crore cash inflow for future growth or debt reduction.
Aditya Infotech (CPPLUS) Q3 FY26 PAT Jumps 139% to ₹96 Cr; Upgrades FY26 and FY27 Guidance
Aditya Infotech (CPPLUS) reported a stellar Q3 FY26 with revenue growing 37.3% YoY to ₹1,139.1 crore and adjusted PAT surging 138.8% to ₹96 crore. The company achieved a record EBITDA margin of 12.6%, driven by a shift toward high-value IP products (75% of portfolio) and operational leverage. Management significantly upgraded its FY26 revenue guidance to ₹3,900-4,100 crore and provided a bullish FY27 revenue target of up to ₹5,550 crore. Strategic moves include a partnership with Qualcomm for AI solutions and backward integration into lens and cable manufacturing.
Key Highlights
Revenue grew 37.3% YoY to ₹1,139.1 crore, while EBITDA surged 98.7% to ₹144.6 crore in Q3 FY26.
Market share in the CCTV segment rose to over 39%, with the CP PLUS brand contributing 87% of total revenue.
Manufacturing capacity increased 20% to 1.9 million units per month, with a target of 2.1 million by Q4 FY26.
Management raised FY26 PAT guidance to 7-7.5% and projected FY27 revenue growth of 30-35% reaching up to ₹5,550 crore.
Announced strategic AI partnership with Qualcomm and backward integration via a new lens assembly line starting Q1 FY27.
👀 What to Watch
Investors should view the guidance upgrade and significant margin expansion as strong indicators of market leadership and pricing power. The shift toward AI-enabled IP solutions and aggressive backward integration provides a long-term competitive moat against global competitors.
Aditya Infotech Q3 FY26: Revenue up 37%, PAT jumps 139% with strong FY27 guidance
Aditya Infotech (CPPLUS) reported a robust Q3 FY26 with revenue growing 37.3% YoY to ₹1,139.1 crores and adjusted PAT surging 138.8% to ₹96 crores. EBITDA margins expanded significantly by 391 bps to 12.6%, driven by a favorable product mix and higher localization. Management has raised its FY26 revenue guidance to ₹3,900-₹4,100 crores and provided a bullish FY27 outlook with revenue targets of ₹5,350-₹5,550 crores. Strategic initiatives include a partnership with Qualcomm for AI solutions and the launch of new mass-market brands EYRA and NEXIVUE.
Key Highlights
Q3 Revenue grew 37.3% YoY to ₹1,139.1 Cr; EBITDA surged 98.7% to ₹144.6 Cr.
EBITDA margins improved by 391 bps to 12.6% due to higher localization and brand mix.
Market share reached over 39% as of Q2 FY26, with CP PLUS brand contributing 87% of revenue.
Management guided for 30-35% revenue growth in FY27, targeting up to ₹5,550 Cr with PAT margins of 7.5%-8.5%.
Manufacturing capacity expanded to 1.9 million units/month, with a target of 2.1 million by Q4 FY26.
👀 What to Watch
Investors should focus on the company's successful margin expansion and aggressive growth guidance for FY27. The shift towards high-margin AI-led solutions and backward integration through new plants in Andhra Pradesh are key long-term value drivers to monitor.
Prakash Pipes Q3 FY26: Net Profit at ₹10 Cr, Sales at ₹181 Cr with Strong Volume Growth
Prakash Pipes Limited reported a Net Profit of ₹10 Crores on Net Sales of ₹181 Crores for the quarter ended December 31, 2025. For the nine-month period, the company achieved a Net Profit of ₹30 Crores with an EPS of ₹12.45. The PVC Pipes division saw volume growth to 11,068 MT, benefiting from stabilized resin prices and strong demand in housing and infrastructure. The Flexible Packaging division also grew its volume to 4,329 MT, supported by capacity expansion and a wider product range.
Key Highlights
Quarterly Net Sales reached ₹181 Crores with an EBITDA of ₹18 Crores.
Net Profit for the nine months ended Dec 2025 stood at ₹30 Crores with an EPS of ₹12.45.
PVC Pipes & Fittings sales volume increased to 11,068 MT from 10,547 MT in the previous year's quarter.
Flexible Packaging division volume grew to 4,329 MT compared to 4,015 MT YoY.
Management indicates that the downward trend in PVC Resin prices has been arrested, supporting business normalcy.
👀 What to Watch
Investors should monitor the sustainability of volume growth in the PVC segment as resin prices stabilize. The company's expansion in the flexible packaging division provides a diversified revenue stream worth watching.
Prakash Pipes Q3 FY26 Net Profit Drops 56% YoY to ₹10.11 Crore
Prakash Pipes Limited reported a significant decline in its financial performance for Q3 FY26, with Net Profit falling 56.2% YoY to ₹10.11 crore. Total revenue from operations decreased by 5.9% YoY to ₹181.15 crore, primarily due to lower realizations despite a growth in sales volumes. The PVC Pipes and Flexible Packaging segments both saw volume growth of 4.9% and 7.8% respectively, but segment margins were heavily compressed. Management remains optimistic about future demand recovery driven by housing, agriculture, and infrastructure sectors.
Key Highlights
Net Profit for Q3 FY26 stood at ₹10.11 crore, a sharp decline from ₹23.11 crore in Q3 FY25.
Revenue from operations fell to ₹181.15 crore compared to ₹192.50 crore in the same period last year.
PVC Pipe sales volume increased to 11,068 MT from 10,547 MT YoY, showing resilient demand despite price volatility.
Flexible Packaging segment profit contracted significantly to ₹1.91 crore from ₹12.80 crore YoY.
Earnings Per Share (EPS) for the quarter dropped to ₹4.23 from ₹9.66 in the previous year's corresponding quarter.
👀 What to Watch
Investors should exercise caution as the company is facing severe margin pressure despite maintaining volume growth. The stock may face short-term pressure until PVC resin prices stabilize and profitability margins show signs of recovery.
Piramal Pharma Resumes Operations at Dahej Site Following GPCB Revocation
Piramal Pharma Limited has received an interim revocation of the closure order for its Dahej manufacturing facility from the Gujarat Pollution Control Board (GPCB). The site, which was previously issued closure directions on February 4 and 12, 2026, under the Water Act, is now authorized to resume operations with immediate effect. This development follows a brief period of regulatory uncertainty regarding the plant's environmental compliance. The company is currently working with the GPCB to ensure the interim directions are made final in due course.
Key Highlights
GPCB granted interim revocation of closure directions for the Dahej site on February 13, 2026
Company authorized to resume operations at the facility with immediate effect
Closure was originally issued under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974
Piramal Pharma is implementing measures to ensure the interim revocation is made final by the GPCB
👀 What to Watch
Investors should view this as a positive resolution to a potential production bottleneck; however, keep an eye on future compliance costs to ensure the revocation becomes permanent.
Piramal Pharma Digwal Facility Receives US FDA Form-483 with 4 Observations
Piramal Pharma Limited's manufacturing facility in Digwal, Telangana, underwent a US FDA inspection from February 9 to February 13, 2026. The inspection concluded with the issuance of a Form-483 containing 4 observations. These observations are procedural in nature and do not involve data integrity issues, which is a positive sign for the company's compliance culture. The US FDA has indicated a classification of Voluntary Action Indicated (VAI), suggesting that the findings are not critical to the facility's operational status.
Key Highlights
US FDA inspection conducted at Digwal, Telangana facility from Feb 9 to Feb 13, 2026
Issuance of Form-483 with 4 observations related to procedural enhancements
No data integrity issues were reported during the inspection
Preliminary classification indicated as Voluntary Action Indicated (VAI)
Company committed to submitting a detailed response within stipulated timelines
👀 What to Watch
Investors should view this as a routine regulatory event with manageable outcomes given the VAI classification and lack of data integrity issues. Monitor for the final Establishment Inspection Report (EIR) to confirm the closure of these observations.
Aditya Infotech (CPPLUS) Q3 PAT Surges 139% YoY to ₹96 Cr; Revenue Up 37%
Aditya Infotech reported a robust Q3 FY26 with revenue growing 37.3% YoY to ₹1,139.1 crore, driven by strong demand for CPPLUS IP cameras. EBITDA margins expanded significantly by 391 bps to 12.7%, resulting in a 138.8% jump in adjusted PAT to ₹96 crore. The company maintains a dominant 38.9% market share in the Indian video surveillance market and is aggressively expanding manufacturing capacities in Kadapa. Management has raised FY26 revenue guidance to the upper end of ₹3,900–4,100 crore with improved margin expectations.
Key Highlights
Q3 FY26 Revenue increased 37.3% YoY to ₹1,139.1 crore with CPPLUS contributing 87% of revenue
EBITDA grew 98.7% YoY to ₹144.6 crore, with margins expanding 391 bps to 12.7%
Adjusted PAT for 9M FY26 rose 138.6% YoY to ₹198.9 crore, excluding a ₹213.1 crore exceptional gain
Capacity expansion at Kadapa facility to reach 2.1 million units per month by Q4 FY26
Raised FY26 guidance: Revenue target ₹3,900–4,100 crore and EBITDA margins of 11–12%
👀 What to Watch
The company exhibits strong fundamental momentum with significant margin expansion and market leadership. Investors should monitor the execution of the new AI-enabled product line with Qualcomm and the commissioning of the lens assembly plant.
Aditya Infotech Q3 Net Profit Surges 139% to ₹96 Cr; Announces JV and Greenfield Expansion
Aditya Infotech (CPPLUS) reported a robust performance for Q3 FY26, with consolidated revenue growing 37.3% YoY to ₹1,139.1 crore. Net profit witnessed a massive jump of 138.8% YoY, reaching ₹96 crore, driven by operational efficiencies. The company is aggressively expanding through a 50:50 JV with Orient Cables for cable manufacturing and a new greenfield project in Kadapa for backward integration of CCTV components. Furthermore, a strategic amendment to the Articles of Association will allow Dixon Technologies to nominate a director to the board, deepening their partnership.
Key Highlights
Consolidated Revenue for Q3 FY26 increased to ₹11,391.1 million from ₹8,295.0 million YoY.
Net Profit for the quarter rose sharply to ₹959.8 million compared to ₹401.9 million in the previous year.
Entered a 50:50 Joint Venture with Orient Cables (India) Limited for manufacturing LAN and CCTV cables.
Subsidiary AIL Dixon Technologies to establish a greenfield facility in Kadapa for plastic and metal housing components.
Proposed AoA amendment to grant Dixon Technologies (India) Limited the right to nominate one Director.
👀 What to Watch
The strong earnings growth combined with strategic backward integration and capacity expansion makes this a positive outlook for long-term investors. Monitor the execution of the greenfield project and the synergy benefits from the Dixon Technologies partnership.
